Direct-acting antiviral (DAA) treatments have made it possible to cure hepatitis C in as few as eight to 12 weeks, with few side effects. For those who have been cured, either with interferon or DAAs, treatment is not the last step in managing their health. People who had been living with hepatitis C for a long time may have extensive damage to their liver, potentially leading to cirrhosis, liver cancer and extrahepatic conditions.
This webinar will explore our clinical understanding of hepatitis C and liver health, the factors that can lead to long-term liver damage for people living with or cured of hepatitis C, and the health needs of people affected by liver injury related to hepatitis C. We will discuss what this means for service providers and how to support people with lived experience of hepatitis C.
Moderator: Shelley Taylor, Specialist, Education and Capacity Building, CATIE
• Dr. Hemant Shah, Clinical Practice Director, Francis Family Liver Clinic; Assistant Professor, University of Toronto
• Michelle Charbonneau, Nurse Practitioner, Cirrhosis Care Clinic, University of Alberta Hospital